Ondine Biomedical Inc. (AIM: OBI), the Canadian life sciences company behind light-activated antimicrobial therapies, has published a health economic analysis estimating that surgical site infections add an average C$2,056 to the cost of every cardiac surgery performed. The analysis, presented at the Canadian Cardiovascular Congress 2026 and published in the Canadian Journal of Cardiology, also models an estimated 10% loss of surgical capacity resulting from infection-related bed-day consumption. The findings are significant for investors tracking the commercial case for Ondine's lead product, Steriwave®, which is authorised for nasal decolonisation in Canada, the UK, and certain other international markets.

Key Points

  • Ondine Biomedical Inc. (AIM: OBI) is a Canadian life sciences company focused on photodisinfection therapies
  • Health economic analysis estimates a C$2,056 per-cardiac-surgery "Infection Tax" attributable to surgical site infections
  • Modelled cohort of 1,000 patients projects over C$2.05 million in incremental costs and 650 additional bed-days consumed by SSIs
  • Investors may be watching whether this economic framing accelerates hospital adoption of Steriwave® pre-operative protocols

C$2,056 Per-Procedure "Infection Tax" Modelled Using Canadian Cardiac Surgery Benchmarks

The analysis applies a baseline cardiac surgery infection rate of 6.7%, drawn from Saunders et al. (2023), and an assumed incremental hospital cost of C$30,689 per infected patient, adapted from Ai et al. (2025) for the Canadian healthcare context. Combining these inputs produces an estimated average "Infection Tax" of C$2,056 per cardiac surgery performed. The company notes that the C$30,689 figure is a modelling assumption adapted from a US cost benchmark, adjusted for exchange rates and healthcare-system differences, rather than a directly measured Canadian cardiac SSI cost. The framework is designed to give hospital administrators a transparent per-procedure metric to evaluate infection-prevention investment.

650 Additional Bed-Days in a 1,000-Patient Cohort Represent an Estimated 100 Lost Elective Procedures

Within the modelled cohort of 1,000 cardiac surgery patients, the projected 67 SSIs would generate more than C$2.05 million in incremental costs and consume 650 additional bed-days, based on an average SSI-related length-of-stay extension of 9.7 days per infected patient. The analysis further estimates that those 650 bed-days could otherwise support approximately 100 elective cardiac procedures, representing an avoidable 10% loss of total surgical capacity. The company highlights that this capacity loss can also contribute to longer surgical waiting lists, a particular concern for public-sector hospital systems managing high patient volumes.

CCC 2026 Presentation Accompanied by University of Ottawa Heart Institute Nasal Photodisinfection Posters

Alongside Ondine's health economics analysis, two related posters from the University of Ottawa Heart Institute were presented at the Canadian Cardiovascular Congress 2026 and published in the Canadian Journal of Cardiology. One examined the implementation of a cardiac surgery SSI prevention bundle incorporating nasal photodisinfection, frontline engagement, and nurse-led advocacy. A second poster reported an interrupted time series analysis of nasal photodisinfection and SSI outcomes following cardiac surgery. These presentations broaden the clinical and operational evidence base surrounding Steriwave®, Ondine's proprietary photodisinfection product, though no specific clinical outcome figures from those posters are detailed in the company's announcement.

Steriwave® Authorised in Canada and UK but Not FDA-Approved for US Commercial Use

Ondine's Steriwave® nasal photodisinfection therapy works by applying a photosensitising agent activated by red light, producing an antimicrobial effect through oxidative mechanisms that the company states carry a low potential for microbial resistance. The product is authorised for nasal decolonisation in Canada, the UK, and certain other international markets. Investors should note that Steriwave® is not approved or cleared by the US Food and Drug Administration and is currently limited to investigational use in the United States. The company also maintains a development pipeline covering chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.